NEW YORK, Nov. 18, 2014 /PRNewswire/ -- This report on cancer diagnostics analyzes the current as well as future prospects of various facets of the market in detail. It provides an in-depth and comprehensive analysis of the cancer diagnostics market. The report includes an elaborate executive summary, which covers a market snapshot representing key findings from the study for various segments such as diagnostic methods, applications, and geography (North America, Europe, Asia-Pacific and Rest of the World).
For the research on this topic, we conducted in-depth interviews and discussions with a wide range of key opinion leaders within cancer diagnostics market, which was supplemented by extensive secondary research. The report provides market size in terms of USD million for each segment for the period 2012 to 2020, considering the macro and micro environmental factors. In addition, the compounded annual growth rate (CAGR) of the overall cancer diagnostics market and the segments has also been provided in the report for the forecast period 2014 to 2020, considering 2012 and 2013 as the base years. Growth rates for each segment within the cancer diagnostics market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements.
The global cancer diagnostics market is categorized based on the diagnostic methods into four major segments, namely, tumor biomarker tests, imaging, endoscopy, and biopsy. The market analysis provided for tumor biomarker tests include revenue from major cancer biomarker tests such as prostate specific antigen (PSA) tests, human epidermal growth factor receptor 2 (HER2) tests, circulating tumor cells (CTC) tests , carcinoembryonic antigen (CEA) test, anaplastic lymphoma kinase (ALK) test, BRCA gene tests, and other tests such as AFP, CA 19-9, CA 125 tests. The report also provides market size for imaging procedures for cancer diagnostics, namely, magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), x-ray and ultrasound imaging. The market size estimation for endoscopies such as colonoscopy, sigmoidoscopy, bronchoscpopy and colposcopy; and biopsies such as bone marrow biopsy, needle biopsy and endoscopic biopsy are provided in the report.
The cancer diagnostics market has been further analyzed for applications such as cancer of lung, breast, colorectal, prostate, liver, blood, and others (cancers of kidney, pancreas, and ovary). According to our estimates, in 2013, lung cancer accounted for the largest share in the global cancer diagnostics market and is expected to continue to grow in the near future. On the basis of geography, the overall global cancer diagnostics market has been segmented into four major regions: North America, Europe, Asia-Pacific, and Rest of the World (ROW). The research study also incorporates a qualitative analysis of the competitive scenario in these regions. A detailed qualitative analysis of the factors responsible for driving and restraining the growth of the cancer diagnostics market and future opportunities has been provided in the market overview section. This section of the report also includes market attractiveness analysis and Porter's five forces analysis. In addition, the study also provides insights into the competitive landscape of the global cancer diagnostics market.
The study is a robust combination of primary and secondary research. Primary research formed the bulk of our research efforts with information collected from telephonic interviews and interaction via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases for patents, clinical trials, demographics, disease incidence/prevalence, etc. The report also profiles major players in the cancer diagnostics market based on various attributes such as company overview, financial overview, business strategies, product portfolio and recent developments. Major players covered in this report are Abbott Laboratories, Ambry Genetics, AstraZeneca plc, bioMerieux SA, Eli Lilly and Company, Genoptix (A Novartis Company), GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd. and Pfizer, Inc.
The global cancer diagnostics market is segmented as follows:
Cancer Diagnostics Market, by Method
Tumor Biomarker Tests
Bone Marrow Biopsy
Cancer Diagnostics Market, by Application
Cancer Diagnostics Market, by Geography
Rest of the World
Read the full report: http://www.reportlinker.com/p02480936-summary/view-report.html
ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - instantly, in one place.
Contact Clare: [email protected]
Intl: +1 339-368-6001